Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients

Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.

Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma

Older individuals are at an increased risk of developing primary central nervous system lymphoma (PCNSL). In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute of New Jersey and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.

Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.